Minster begins phase 2 trial in prevention of migraine

By Elaine Rigoli

Tampa, Fla., March 21 - Minster Pharmaceuticals plc said it has recruited the first patients in a multinational phase 2 clinical trial of tonabersat, the company's lead compound in the prevention of migraine.

The first patients have been recruited to the Danish Headache Centre at Glostrup Hospital, Copenhagen, which will be followed by patient recruitment at centers in the United Kingdom, Hungary and South Africa.

The trial will enroll about 130 patients, who will take either tonabersat or a placebo on a once-daily basis for three months, according to a news release.

The primary endpoint of the trial will be the reduction in the number of days that patients suffer a migraine, the release said.

The trial results are expected during the first quarter of 2007.

Tonabersat is part of a new class of drugs called gap junction blockers, which are the subject of significant interest from clinicians and pharmaceutical researchers for their potential in the prevention of migraine as an alternative to current acute treatments, the release said.

Minster Pharmaceuticals acquired rights to tonabersat in early 2001 from GlaxoSmithKline, which conducted extensive toxicological and clinical studies on the compound, establishing its safety profile and providing promising evidence of activity in the treatment of migraines.

Minster Pharmaceuticals, a drug-development company specializing in neurological and psychiatric disorders, has headquarters in Essex, U.K.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.